- Understand $clls stock

$CLLS Market Cap: $145.6 Million

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$27.78M

TTM

Gross Margin

-258.21%

TTM

Net Earnings

-$91.81M

TTM

Current Assets

$305.8M

Q2 2024

Current Liabilities

$159.6M

Q2 2024

Current Ratio

191.57%

Q2 2024

Total Assets

$407.1M

Q2 2024

Total Liabilities

$258.5M

Q2 2024

Book Value

$148.6M

Q2 2024

Cash

$90.35M

Q2 2024

P/E

-1.586

Sep 18, 2024 EST

Free Cash Flow

$49.64M

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$9.193M	$25.73M	$67.07M	$82.46M	$22.99M	$21.43M	$33.72M	$56.44M	$62.57M	$23.83M	$10.23M	$14.52M	$13.81M	$10.81M	$10.59M	$15.51M	$1.980M	$1.490M	$7.340M	$870.0K	$1.070M	$610.0K
YoY Change	-64.26%	-61.65%	-18.66%	258.66%	7.27%	-36.43%	-40.27%	-9.78%	162.56%	132.93%	-29.55%	5.14%	27.75%	2.08%	-31.72%	683.33%	32.89%	-79.7%	743.68%	-18.69%	75.41%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Revenue	$9.193M	$25.73M	$67.07M	$82.46M	$22.99M	$21.43M	$33.72M	$56.44M	$62.57M	$23.83M	$10.23M	$14.52M	$13.81M	$10.81M	$10.59M	$15.51M	$1.980M	$1.490M	$7.340M	$870.0K	$1.070M	$610.0K
Cost Of Revenue	$39.68M	$44.45M	$75.34M	$56.63M	$60.68M	$54.71M	$47.60M	$36.57M	$23.69M	$9.295M	$18.26M	$17.74M	$24.69M	$15.31M	$16.76M	$1.620M	$1.390M	$3.680M	$2.770M	$2.020M	$1.070M	$760.0K
Gross Profit	-$30.49M	-$18.72M	-$8.273M	$25.83M	-$37.69M	-$33.28M	-$13.88M	$19.87M	$38.88M	$14.53M	-$8.030M	-$3.210M	-$10.88M	-$4.490M	-$6.170M	$13.89M	$600.0K	-$2.190M	$4.560M	-$1.150M	-$10.00K	-$140.0K
Gross Profit Margin	-331.61%	-72.78%	-12.33%	31.32%	-163.95%	-155.27%	-41.17%	35.2%	62.14%	60.99%	-78.49%	-22.11%	-78.78%	-41.54%	-58.26%	89.56%	30.3%	-146.98%	62.13%	-132.18%	-0.93%	-22.95%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Selling, General & Admin	$16.81M	$17.49M	$67.69M	$58.72M	$54.24M	$49.55M	$49.69M	$50.33M	$42.24M	$16.03M	$23.57M	$18.28M	$7.440M	$4.430M		$6.320M	$4.270M	$2.980M	$2.760M	$2.380M	$2.670M	$2.040M
YoY Change	-3.9%	-74.15%	15.27%	8.26%	9.47%	-0.28%	-1.29%	19.17%	163.51%	-32.0%	28.94%	145.7%	67.95%			48.01%	43.29%	7.97%	15.97%	-10.86%	30.88%
% of Gross Profit				227.34%				253.31%	108.63%	110.28%						45.5%	711.67%		60.53%
Research & Development	$87.65M	$97.50M	$10.85M	$8.029M	$12.26M	$18.06M	$23.83M	$33.21M	$20.56M	$8.186M	$21.42M	$15.45M	$17.11M	$16.30M	$11.09M
YoY Change	-10.11%	798.46%	35.16%	-34.51%	-32.1%	-24.23%	-28.23%	61.49%	151.19%	-61.78%	38.64%	-9.7%	4.97%	46.98%
% of Gross Profit				31.09%				167.12%	52.89%	56.33%
Depreciation & Amortization	$18.52M	$18.44M	$16.57M	$9.819M	$6.875M	$2.377M	$3.371M	$2.211M	$1.937M	$1.542M	$44.17M	$4.710M	$3.000M	$1.570M	$1.100M	$510.0K	$800.0K	$540.0K	$540.0K	$190.0K	$430.0K	$140.0K
YoY Change	0.48%	11.26%	68.75%	42.82%	189.23%	-29.49%	52.46%	14.15%	25.61%	-96.51%	837.79%	57.0%	91.08%	42.73%	115.69%	-36.25%	48.15%	0.0%	184.21%	-55.81%	207.14%
% of Gross Profit				38.02%				11.13%	4.98%	10.61%						3.67%	133.33%		11.84%
Operating Expenses	$104.5M	$115.0M	$122.4M	$111.3M	$85.86M	$71.81M	$78.77M	$87.17M	$69.86M	$20.31M	$35.39M	$21.99M	$16.28M	$10.82M	$7.170M	$18.93M	$7.890M	$2.480M	$6.120M	$3.050M	$3.450M	$2.130M
YoY Change	-9.16%	-6.05%	10.01%	29.59%	19.56%	-8.83%	-9.64%	24.77%	243.94%	-42.6%	60.94%	35.07%	50.46%	50.91%	-62.12%	139.92%	218.15%	-59.48%	100.66%	-11.59%	61.97%
Operating Profit	-$134.9M	-$133.7M	-$130.7M	-$85.44M	-$123.6M	-$105.1M	-$92.65M	-$67.30M	-$30.98M	-$5.779M	-$43.42M	-$25.20M	-$27.16M	-$15.31M	-$13.34M	-$5.040M	-$7.290M	-$4.670M	-$1.560M	-$4.200M	-$3.460M	-$2.270M
YoY Change	0.92%	2.33%	52.95%	-30.85%	17.57%	13.43%	37.66%	117.22%	436.16%	-86.69%	72.3%	-7.22%	77.4%	14.77%	164.68%	-30.86%	56.1%	199.36%	-62.86%	21.39%	52.42%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Interest Expense	-$18.04M	$371.0K	$5.128M	-$12.38M	$8.189M	$17.25M	-$14.58M	$2.252M	$8.319M	$7.916M	-$400.0K	-$1.580M	$210.0K	$480.0K	$400.0K	$1.170M	$760.0K	-$80.00K	-$50.00K
YoY Change	-4963.61%	-92.77%	-141.42%	-251.19%	-52.52%	-218.32%	-747.34%	-72.93%	5.09%	-2079.1%	-74.68%	-852.38%	-56.25%	20.0%	-65.81%	53.95%	-1050.0%	60.0%
% of Operating Profit
Other Income/Expense, Net	-$1.119M	-$12.33M	$442.0K	$335.0K	$151.0K	-$490.0K	$3.545M	-$2.205M	$59.00K	-$99.16K	-$50.00K	-$110.0K	-$20.00K	$40.00K	$0.00	$0.00	$0.00	-$1.590M	-$250.0K	$120.0K	$150.0K	$160.0K
YoY Change	-90.92%	-2888.91%	31.94%	121.85%	-130.82%	-113.82%	-260.77%	-3837.29%	-159.5%	98.32%	-54.55%	450.0%	-150.0%				-100.0%	536.0%	-308.33%	-20.0%	-6.25%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Pretax Income	-$116.5M	-$98.60M	-$125.1M	-$97.48M	-$115.2M	-$88.33M	-$103.7M	-$67.26M	-$22.61M	$2.038M	-$77.97M	-$27.09M	-$26.97M	-$14.84M	-$12.94M	-$3.870M	-$6.550M	-$4.530M	-$1.520M	-$3.890M	-$3.300M	-$2.120M
YoY Change	18.12%	-21.19%	28.34%	-15.39%	30.43%	-14.8%	54.16%	197.51%	-1209.05%	-102.61%	187.82%	0.44%	81.74%	14.68%	234.37%	-40.92%	44.59%	198.03%	-60.93%	17.88%	55.66%
Income Tax	$371.0K	$87.00K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$4.500M	$1.530M	$6.180M	-$3.840M	-$2.180M	-$4.070M	-$2.450M	-$270.0K	-$560.0K	-$660.0K	-$240.0K	-$150.0K
% Of Pretax Income										0.0%
Net Earnings	-$108.4M	-$114.0M	-$114.2M	-$81.07M	-$102.1M	-$78.69M	-$99.37M	-$67.26M	-$22.80M	$22.04K	-$81.04M	-$28.09M	-$33.15M	-$10.99M	-$10.77M	$190.0K	-$4.090M	-$4.260M	-$960.0K	-$3.230M	-$3.060M	-$1.980M
YoY Change	-4.9%	-0.14%	40.86%	-20.59%	29.73%	-20.81%	47.75%	195.03%	-103548.9%	-100.03%	188.5%	-15.26%	201.64%	2.04%	-5768.42%	-104.65%	-3.99%	343.75%	-70.28%	5.56%	54.55%
Net Earnings / Revenue	-1179.63%	-443.28%	-170.26%	-98.32%	-444.07%	-367.18%	-294.73%	-119.15%	-36.44%	0.09%	-792.18%	-193.46%	-240.04%	-101.67%	-101.7%	1.23%	-206.57%	-285.91%	-13.08%	-371.26%	-285.98%	-324.59%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.77	-$2.33	-$2.548M	-$1.907M	-$2.405M	-$1.930M	-$2.784M	-$1.907M	-$667.5K	$841.30	-$3.924M	-$1.409M	-$2.697M	-$943.3K	-$1.074M	$20.67K	-$445.0K	-$838.6K	-$189.0K	-$635.8K	-$602.4K	-$389.8K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Cash & Short-Term Investments	$203.8M	$97.70M	$186.1M	$268.2M	$360.9M	$451.9M	$297.0M	$291.2M			$123.8M	$28.80M	$54.90M	$32.20M	$64.50M	$39.90M	$36.80M	$6.200M	$9.100M	$2.600M	$7.000M	$8.700M
YoY Change	108.62%	-47.51%	-30.61%	-25.68%	-20.13%	52.16%	2.0%				329.8%	-47.54%	70.5%	-50.08%	61.65%	8.42%	493.55%	-31.87%	250.0%	-62.86%	-19.54%
Cash & Equivalents	$55.00M	$97.70M	$47.91M	$76.56M	$69.89M	$53.32M	$297.0M	$69.07M			$19.47M	$26.70M	$51.40M	$31.50M	$59.00M	$39.90M	$36.80M	$6.200M	$9.100M	$2.600M	$7.000M	$8.700M
Short-Term Investments	$67.11M	$21.49M	$499.0K	$27.09M	$20.39M	$388.0K					$0.00
Other Short-Term Assets	$6.060M	$9.078M	$8.221M	$26.32M	$12.42M	$13.41M	$11.30M	$6.980M	$1.049M	$4.227M	$5.280M	$1.100M	$800.0K	$1.000M	$1.400M	$7.200M	$5.200M	$500.0K	$100.0K	$0.00	$0.00	$0.00
YoY Change	-33.25%	10.42%	-68.77%	111.89%	-7.36%	18.71%	61.83%	565.37%	-75.18%	-19.94%	379.98%	37.5%	-20.0%	-28.57%	-80.56%	38.46%	940.0%	400.0%
Inventory		$0.00	$0.00	$1.606M	$2.897M	$275.0K	$250.0K	$118.0K			$148.7K	$900.0K	$800.0K	$200.0K	$200.0K	$200.0K	$200.0K	$200.0K	$100.0K	$100.0K	$0.00	$100.0K
Prepaid Expenses
Receivables	$569.0K	$772.0K	$20.36M	$5.171M	$2.959M	$2.971M	$2.753M	$3.627M			$6.480M	$8.000M	$5.200M	$3.300M	$2.500M	$1.000M	$600.0K	$900.0K	$1.600M	$500.0K	$600.0K	$200.0K
Other Receivables	$22.56M	$14.50M	$10.71M	$14.02M	$12.33M	$19.10M	$11.94M	$10.61M			$9.002M	$12.50M	$8.900M	$11.20M	$4.400M	$0.00	$0.00	$3.900M	$2.500M	$1.900M	$900.0K	$1.100M
Total Short-Term Assets	$233.0M	$122.0M	$225.4M	$315.4M	$391.5M	$487.6M	$323.2M	$312.5M	$1.049M	$4.227M	$145.4M	$51.30M	$70.50M	$47.80M	$73.00M	$48.30M	$42.80M	$11.70M	$13.40M	$5.200M	$8.700M	$10.10M
YoY Change	90.92%	-45.86%	-28.52%	-19.45%	-19.71%	50.87%	3.43%	29688.95%	-75.18%	-97.09%	183.5%	-27.23%	47.49%	-34.52%	51.14%	12.85%	265.81%	-12.69%	157.69%	-40.23%	-13.86%
Property, Plant & Equipment	$92.74M	$107.9M	$148.3M	$145.5M	$69.32M	$10.04M	$7.226M	$16.90M			$2.876M	$7.200M	$8.600M	$5.200M	$4.100M	$2.000M	$1.500M	$2.400M	$2.000M	$2.300M	$700.0K	$400.0K
YoY Change	-14.05%	-27.23%	1.89%	109.91%	590.41%	38.96%	-57.24%				-60.06%	-16.28%	65.38%	26.83%	105.0%	33.33%	-37.5%	20.0%	-13.04%	228.57%	75.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$7.853M	$8.791M	$6.524M	$7.007M	$5.517M	$1.891M	$1.004M	$691.0K			$2.178M	$1.900M	$1.200M	$300.0K	$300.0K	$400.0K	$100.0K	$100.0K	$100.0K	$0.00	$0.00	$0.00
YoY Change	-10.67%	34.75%	-6.89%	27.01%	191.75%	88.35%	45.3%				14.64%	58.33%	300.0%	0.0%	-25.0%	300.0%	0.0%	0.0%
Other Assets	$0.00	$21.77M				-$1.000K		$0.00			$0.00	$4.500M	$5.800M	$10.50M	$7.100M	$10.30M	$9.600M				$0.00	$0.00
YoY Change	-100.0%										-100.0%	-22.41%	-44.76%	47.89%	-31.07%	7.29%
Total Long-Term Assets	$101.3M	$139.2M	$156.6M	$154.1M	$75.95M	$13.20M	$9.661M	$18.93M			$6.184M	$63.50M	$61.20M	$21.40M	$12.90M	$12.80M	$11.10M	$3.000M	$2.400M	$2.600M	$900.0K	$500.0K
YoY Change	-27.24%	-11.16%	1.65%	102.91%	475.41%	36.62%	-48.98%				-90.26%	3.76%	185.98%	65.89%	0.78%	15.32%	270.0%	25.0%	-7.69%	188.89%	80.0%
Total Assets	$334.3M	$261.2M	$382.1M	$469.5M	$467.5M	$500.8M	$332.9M	$331.4M			$151.6M	$114.8M	$131.7M	$69.20M	$85.90M	$61.10M	$53.90M	$14.70M	$15.80M	$7.800M	$9.600M	$10.60M
YoY Change
Accounts Payable	$19.07M	$21.46M	$23.76M	$24.61M	$29.26M	$15.88M	$9.460M	$9.722M			$10.80M	$14.20M	$12.60M	$9.700M	$8.300M	$7.800M	$6.600M	$5.800M	$4.000M	$1.300M	$900.0K	$800.0K
YoY Change	-11.13%	-9.7%	-3.44%	-15.91%	84.25%	67.9%	-2.69%				-23.95%	12.7%	29.9%	16.87%	6.41%	18.18%	13.79%	45.0%	207.69%	44.44%	12.5%
Accrued Expenses	$9.368M	$9.421M	$12.48M	$13.24M	$7.295M	$7.041M	$5.982M		$4.578M	$744.4K	$1.598M	$1.800M	$100.0K	$200.0K				$700.0K	$700.0K	$600.0K	$700.0K	$500.0K
YoY Change	-0.56%	-24.53%	-5.68%	81.43%	3.61%	17.7%			515.0%	-53.41%	-11.24%	1700.0%	-50.0%					0.0%	16.67%	-14.29%	40.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00			$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.502M	$7.872M	$8.329M	$6.696M	$1.067M	$333.0K	$21.00K	$38.00K			$949.7K	$1.300M	$1.400M	$1.100M	$1.200M			$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	8.0%	-5.49%	24.39%	527.55%	220.42%	1485.71%	-44.74%				-26.94%	-7.14%	27.27%	-8.33%
Total Short-Term Liabilities	$155.1M	$48.13M	$49.35M	$52.02M	$62.60M	$46.87M	$45.45M	$56.17M	$4.578M	$744.4K	$82.49M	$28.30M	$26.80M	$17.00M	$19.10M	$12.80M	$8.200M	$6.700M	$5.000M	$2.300M	$1.600M	$1.400M
YoY Change	222.34%	-2.47%	-5.13%	-16.91%	33.57%	3.12%	-19.08%	1127.02%	515.0%	-99.1%	191.47%	5.6%	57.65%	-10.99%	49.22%	56.1%	22.39%	34.0%	117.39%	43.75%	14.29%
Long-Term Debt	$92.07M	$69.89M	$91.56M	$104.6M	$46.54M	$1.018M	$13.00K	$30.00K			$61.70K	$1.000M	$67.40M	$1.900M	$1.800M	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	31.74%	-23.67%	-12.47%	124.75%	4471.71%	7730.77%	-56.67%				-93.83%	-98.52%	3447.37%	5.56%
Other Long-Term Liabilities	$2.200M	$17.26M	$4.698M	$4.010M	$2.855M	$2.681M	$3.431M	$560.0K			$3.488M	$4.000M	$500.0K	$200.0K	$200.0K	$1.800M	$2.100M	$8.800M	$7.600M	$700.0K	$400.0K	$0.00
YoY Change	-87.25%	267.28%	17.16%	40.46%	6.49%	-21.86%	512.68%				-12.79%	700.0%	150.0%	0.0%	-88.89%	-14.29%	-76.14%	15.79%	985.71%	75.0%
Total Long-Term Liabilities	$94.27M	$87.14M	$96.25M	$108.6M	$49.40M	$3.699M	$3.444M	$590.0K			$3.550M	$5.000M	$67.90M	$2.100M	$2.000M	$1.800M	$2.100M	$8.800M	$7.600M	$700.0K	$400.0K	$0.00
YoY Change	8.18%	-9.46%	-11.38%	119.88%	1235.36%	7.4%	483.73%				-29.0%	-92.64%	3133.33%	5.0%	11.11%	-14.29%	-76.14%	15.79%	985.71%	75.0%
Total Liabilities	$249.6M	$143.2M	$160.8M	$193.9M	$152.3M	$91.54M	$68.01M	$58.64M			$84.65M	$36.10M	$94.70M	$19.10M	$21.10M	$14.70M	$10.30M	$15.60M	$12.60M	$3.100M	$2.000M	$1.400M
YoY Change	74.23%	-10.91%	-17.08%	27.27%	66.43%	34.59%	15.98%				134.48%	-61.88%	395.81%	-9.48%	43.54%	42.72%	-33.97%	23.81%	306.45%	55.0%	42.86%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Dividends

Stock Price

Market Cap: $145.63 Million

About

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 235 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.

Industry: Biological Products, (No Diagnostic Substances) Peers: